News | Heart Failure | October 02, 2015

ENCORE Study Finds Autonomic Regulation Therapy Benefits Extend Beyond 12 Months

Patients in extension of ANTHEM-HF study showed continued improvement in heart pump function, reduction in heart failure symptom burden

October 2, 2015 — Cyberonics Inc. announced results from the extension of the ANTHEM-HF clinical study (ENCORE Study). Results of the study presented by a prominent heart failure (HF) specialist during a major cardiology congress in the United States show that autonomic regulation therapy (ART) in patients with moderate to severe chronic HF and impaired heart function is well-tolerated, safe, improves the heart's ability to pump blood, and reduces the frequency and severity of symptoms associated with chronic HF. More than 10 million people in the United States and Europe have chronic HF, a syndrome characterized by the heart's inability to pump sufficient blood to meet the metabolic demands of the body.

Results from the ENCORE clinical study were presented during a late breaking clinical trials session at the 19th Annual Meeting of the Heart Failure Society of America (HFSA) and showed that patients with chronic, reduced ejection fraction HF on stable pharmacological therapy and treated with ART for 12 months via electrical stimulation of the cervical vagus nerve experienced a statistically and clinically significant:

  • Improvement in heart pump function: Average left ventricular ejection fraction increased from 33.2 percent at baseline to 39.5 percent; average left ventricular end-systolic volume decreased 10 percent from 102 ml to 92 ml;
  • Reduction in HF symptom burden: New York Heart Association (NYHA) class improved in 94 percent of patients;
  • Improvement in quality of life (assessed by Minnesota Living with HF Questionnaire);
  • Increase in functional capacity (assessed by six-minute walk distance); and
  • Improvement in autonomic regulation of resting heart rate.

University of Minnesota Professor of Medicine Inder Anand, M.D., D.Phil. (Oxon), chair of the ANTHEM-HF clinical study steering committee and until recently director of the Heart Failure Program, VA Medical Center, Minneapolis, Minnesota, commented, "Patients with heart failure continue to be at high risk of increased morbidity and mortality. They need new therapies, such as ART, that work synergistically with evolving forms of drug therapy. The results from the extension of the ANTHEM-HF study presented during a late breaking clinical trials session at HFSA provide important insights into the safety and durability of ART. During the 6- to 12-month follow-up period, none of the patients experienced serious adverse events related to ART, and the improvements in cardiac function both in terms of ejection fraction and reverse remodeling suggest that ART is ready to be tested in a randomized, control trial in which a larger cohort of optimally-managed chronic HF patients from the U.S. and the EU would be randomized to a treatment group and a control group to more extensively evaluate safety and efficacy."

Sponsored by Cyberonics, the ENCORE study was a prospective, multi-center, open-label, extension of the ANTHEM-HF study during which the effects of ART were evaluated in chronic HF patients with NYHA Class II and III heart failure, QRS complex interval less than 150 milliseconds, and reduced heart pumping function (left ventricular ejection fraction less than 40 percent). According to investigators, patients enrolled in the study received optimal HF pharmacological therapy prior to and during all phases of study.

Forty-nine patients previously enrolled in the ANTHEM-HF study elected to participate in the ENCORE study and received ART for an additional 6 months (12 months total). All patients received continuously cyclic, natural-frequency ART previously described in the publication of ANTHEM-HF results. Safety was assessed throughout the ENCORE study and outcome measures were assessed after 12 months of ART and compared to baseline values of the ENCORE cohort.

For more information: www.cyberonics.com

Related Content

Cardiac Dimensions Randomizes First Patient in CARILLON Trial of Mitral Contour System
News | Heart Failure | September 20, 2018
Cardiac Dimensions announced the company has randomized its first patient in the CARILLON Pivotal Trial.
Antithrombin Drug Ineffective in Heart Failure With Sinus Rhythm and Coronary Disease
News | Heart Failure | September 07, 2018
The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction...
Tafamidis Improves Survival in Rare Heart Condition
News | Heart Failure | September 06, 2018
Tafamidis is the first treatment to improve survival and reduce hospitalizations in a rare heart condition called...
New Target for Treating Heart Failure Identified by Penn Medicine Researchers

Microtubules in heart cells from a healthy patient (left) and from a patient with heart failure. The dense network of detyrosinated microtubules impedes the motion of the failing heart cell during the heart beat. Credit: Ben Prosser lab, Perelman School of Medicine, University of Pennsylvania

News | Heart Failure | June 25, 2018
New research finds changes in cellular struts called microtubules (MT) can affect the stiffness of diseased human heart...
Gencaro Does Not Reduce Atrial Fibrillation Risk in Heart Failure Patients
News | Heart Failure | May 30, 2018
Data from the GENETIC-AF trial was presented in a “Late Breaking Clinical Trials” oral presentation at the European...
Cardiac Contractility Modulation Safe and Effective as Heart Failure Treatment

Image courtesy of Impulse Dynamics

News | Heart Failure | May 18, 2018
In a new study, cardiac contractility modulation (CCM) therapy was confirmed to significantly improve exercise...
V-Wave Closes $70M Financing to Support Pivotal Study of Heart Failure Therapy
News | Heart Failure | May 16, 2018
Israel-based V-Wave Ltd. recently closed a $70 million Series C financing for its proprietary, minimally invasive...
News | Heart Failure | May 14, 2018
Ancora Heart Inc. announced the expansion of the company’s U.S. feasibility study to evaluate the investigational...
Protein Clumping May Contribute to Heart Failure Development

A PET scan detects clumping proteins in rat hearts (top). The enlarged heart (right) is one with heart failure. Other PET scans showing blood flow in the rat hearts (bottom) show that the protein clumps aren't due to circulation problems. Image courtesy of Circulation Research, May 11, 2018.

News | Heart Failure | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
Overlay Init